[Anti-cancer agents nephrotoxicity]

Mariusz Mieczkowski1, Joanna Matuszkiewicz-Rowińska1, Małgorzata Kościelska1

  • 1Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych, Warszawski Uniwersytet Medyczny, Warszawa.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|May 11, 2016
PubMed

Insights

Chemotherapy can cause various kidney injuries, including tubular damage and podocytopathies. This article summarizes the diagnosis, treatment, and prevention of these chemotherapy-induced nephrotoxicities.

Area of Science:

  • Nephrology
  • Oncology
  • Pharmacology

Context:

  • Chemotherapy is a cornerstone of cancer treatment.
  • Nephrotoxicity is a significant and common adverse effect of anti-cancer drugs.
  • Understanding chemotherapy-induced kidney injury is crucial for patient management.

Purpose:

  • To provide a concise overview of chemotherapy-induced nephrotoxicity.
  • To summarize the diverse forms of kidney injury caused by anti-cancer agents.
  • To outline diagnostic, therapeutic, and preventive strategies for managing these conditions.

Summary:

  • Chemotherapy can lead to acute and chronic tubular injuries, podocytopathies, crystal nephropathies, thrombotic microangiopathy, and electrolyte wasting syndromes.
  • The article covers the pathological changes associated with these conditions.
  • Key aspects of diagnosis, treatment, and prevention are discussed.

Impact:

  • Improved clinical recognition and management of chemotherapy-related kidney problems.
  • Enhanced patient outcomes through timely intervention and prophylaxis.
  • Foundation for further research into mitigating anti-cancer drug nephrotoxicity.

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
458
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
727
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
145
Physical Properties of Amines01:26

Physical Properties of Amines

Amines with low molecular weight are usually gaseous at room temperature, while those with high molecular weight are liquid or solids in nature. Usually, low molecular weight amines have a rotten fish-like smell. Diamines typically have a pungent smell. For instance, cadaverine and putrescine, depicted in Figure 1, are two molecules responsible for decaying tissue.
4.4K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
571
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K